araag2/HINT huggingface dataset:
Clinical trial NCT00430118 (phase 3, status: completed)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine sulfate, vindesine
SMILES: N[C@@H](CC(O)=O)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O, S=C1N=CNC2=C1NC=N2, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, NC1=NC(=S)C2=C(N1)N=CN2, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@@H]5C[N@@](C[C@](O)(CC)C5)CCC5=C4NC4=CC=CC=C54)C(=O)OC)N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(N)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed acute lymphoblastic leukemia (ALL)

          -  No secondary ALL

        PATIENT CHARACTERISTICS:

          -  No prior disease that would preclude treatment with chemotherapy

        PRIOR CONCURRENT THERAPY:

          -  More than 4 weeks since prior chemotherapy

          -  More than 4 weeks since prior steroids
Clinical trial NCT00605293 (phase 3, status: completed)
Conditions: anemia
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: methoxy polyethylene glycol-epoetin beta, epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  chronic renal anemia;

          -  continuous iv maintenance epoetin alfa therapy, with the same dosing interval during
             the previous month to and during SVP;

          -  regular hemodialysis for greater than or equal to (>=) 3 months

        Exclusion Criteria:

          -  transfusion of red blood cells during previous 2 months

          -  poorly controlled hypertension requiring interruption of epoetin alfa treatment in
             previous 6 months;
Clinical trial NCT00331864 (phase 3, status: completed)
Conditions: age related macular degeneration, choroidal neovascularization
ICD codes: H35.3130, H35.3230, H35.3110, H35.3120, H35.3131, H35.3132, H35.3190, H44.2A1, H44.2A2, H44.2A3, H44.2A9, H35.3231, H35.3232, H35.3211
Drugs: ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Patients who participated in this study included those who had completed participation in
        the study CRFB002A2301 (ANCHOR; NCT00061594), newly diagnosed patients, as well as
        previously diagnosed patients who had had recent disease progression.

        Inclusion Criteria:

          -  Male or female patients > 50 years of age

          -  Diagnosis of active primary or recurrent CNV secondary to AMD, including those with
             predominantly classic, minimally classic or occult lesions with no classic component

          -  The total area of CNV (including both classic and occult components) encompassed
             within the lesion must be >= 50% of the total lesion area

          -  The total lesion area must be <= 12 disc areas

          -  Patients who have a BCVA (best corrected visual acuity) score between 73 and 24
             letters, inclusive, in the study eye using ETDRS-like (Early Treatment of Diabetic
             Retinopathy Study) grading charts (approximately 20/40 to 20/320)

        Exclusion Criteria:

          -  Patients who have a BCVA of < 34 letters in both eyes (legally blind is defined as
             bilateral vision below 20/200 or less than 34 letters)

          -  Laser photocoagulation, treatment with intravitreal steroids, verteporfin photo
             dynamic therapy or pegaptanib sodium in the study eye within 30 days preceding Day 1

          -  Previous participation in a clinical trial (for either eye) involving anti-angiogenic
             drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase C inhibitors, etc.)

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00516139 (phase 3, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: lamotrigine
SMILES: NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
Eligibility criteria:

        Inclusion criteria:

          -  Confident diagnosis of epilepsy

          -  Currently treated with one or two antiepileptic medications

          -  Able to complete a seizure diary

        Exclusion criteria:

          -  History of hypersensitivity to lamotrigine

          -  Progressive diseases that would interfere with the study objectives
Clinical trial NCT00124982 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: abatacept, non-biologic disease modifying anti-rheumatic drug (dmard), anti-tumor necrosing factor (tnf) therapy
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
Eligibility criteria:

        Inclusion Criteria:

          -  Completed double-blind portion of the IM101064 study.

          -  Rheumatoid arthritis (RA) for greater than 1 year from the time of initial diagnosis

          -  American College of Rheumatology (ACR) functional class I, II, III

          -  Subjects currently or previously received an anti-TNF therapy at an approved labeled
             dose for at least 3 months

        Exclusion Criteria:

          -  Subjects with active vasculitis of a major organ system (except subcutaneous
             rheumatoid nodules)

          -  History of cancer within the last 5 years (other than non-melanoma skin cell cancers
             cured by local resection)
Clinical trial NCT00670306 (phase 3, status: completed)
Conditions: benign prostatic hypertrophy
ICD codes: J35.3, J35.1, J35.2, N28.81, N62, N85.2, J34.3
Drugs: cetrorelix pamoate
SMILES: CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Benign Prostatic Hyperplasia, based on medical history

          -  Voiding symptoms

          -  Uroflow (max) 5-15mL/sec

        Exclusion Criteria:

          -  Urgent need for prostate surgery

          -  History of allergic reaction to peptide

          -  Major organ dysfunction

          -  Prior surgical treatment of the prostate or bladder

          -  Current or recent treatment with sexual hormone drugs or 5 α reductase inhibitors or
             botulinum toxin type a (Botox) within the last 6 months prior to trial medication at
             Week 0 or with α blockers or saw palmetto within the last 6 weeks prior to trial
             medication at Week 0

          -  Urologic disorders including neurogenic bladder dysfunction due to diabetes mellitus
             or documented neurologic disorder, urethral stricture disease or history of pelvic
             radiation therapy

          -  History of acute obstructive, infectious, or neurological disorders of the
             genitourinary tract within the last 3 months
Clinical trial NCT00662714 (phase 3, status: completed)
Conditions: cystic fibrosis, diabetes mellitus
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4, P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: repaglinide, short-acting insulin (actrapid)
SMILES: CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

        Inclusion Criteria for the Screening:

          -  Diagnosed cystic fibrosis

          -  Age 10 years and older

        Inclusion Criteria for the therapeutic part of the study:

          -  Newly diagnosed Diabetes mellitus in the screening

        Exclusion Criteria:

        Exclusion Criteria for Screening:

          -  Diabetic keto-acidosis (blood glucose > 350 mg/dl and arterial pH < 7.25)

          -  Already treated Diabetes mellitus by oral antidiabetic medication or insulin

        Exclusion Criteria for the therapeutic part of the study:

          -  Systemic steroid therapy during the last 3 months

          -  Transplantation (status post TX or on the waiting list for TX)

          -  Beginning pulmonary insufficiency, FEV1 < 35% at pulmonary function test in stable
             condition

          -  Pregnancy

          -  Already diagnosed and treated diabetes mellitus

          -  Patients with diabetic keto-acidosis (blood glucose > 350 mg/dl and arterial pH <
             7.25) with or without diabetic coma

          -  Severe liver insufficiency (chronic hepatitis B, AST or ALT twice the upper limit of
             normal, Quick's value < 70% which is a contraindication to use Repaglinide)

          -  Treatment with an indispensable important drug which contraindicates Repaglinide

          -  PEG/ gastric tube/ total parenteral alimentation for more than 4 weeks during the
             study

          -  CF-patients with type 1 diabetes

          -  Not patient's consent to randomisation and therapeutic trial

          -  Participation on other medical trial
Clinical trial NCT00337727 (phase 3, status: completed)
Conditions: chemotherapy-induced nausea and vomiting
ICD codes: D61.810
Drugs: aprepitant, comparator: ondansetron, comparator: dexamethasone, comparator: fosaprepitant dimeglumine, comparator; placebo (unspecified), comparator; placebo (unspecified)
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients will be naive to emetogenic chemotherapy with histologically or cytologically
             confirmed malignant disease scheduled to receive a single dose of moderately
             emetogenic chemotherapy on study day 1

          -  Karnofsky score of 60 or greater

        Exclusion Criteria:

          -  Patient is scheduled to receive any dose of cisplatin

          -  Patient will receive abdominal or pelvic radiation a week prior and up to 6 days after
             initiation of chemotherapy

          -  Any allergies to study drug or antiemetics

          -  Taking CYP3A4 substrates/prohibited medication

          -  Significant medical or mental conditions

          -  Abnormal laboratory values (platelets, absolute neutrophils, AST, ALT, bilirubin or
             creatinine).
Clinical trial NCT00722852 (phase 3, status: completed)
Conditions: osteoarthritis of the knee
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: ketoprofen in diractin®, placebo
SMILES: CC(C(O)=O)C1=CC(=CC=C1)C(=O)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent signed and dated

          -  Age > 45 years

          -  Class I-III OA of the knee and subject meets American College of Rheumatology (ACR)
             clinical classification criteria for osteoarthritis of the knee

        Exclusion Criteria:

          -  Skin lesions or dermatological diseases in the treatment area

          -  Directly or indirectly involved in the conduct and administration of this study

          -  Received any investigational medicinal product within 30 days prior to Screening Visit
             or participation in any previous clinical study with Diractin®

          -  Pregnancy or lactation

          -  Residents of psychiatric wards, prisons or other state institutions

          -  Malignancy within the past 2 years

          -  Depressive disorders requiring treatment with tricyclics, treatment with other
             antidepressants must be stable for 3 months prior to screening and throughout the
             study

          -  Epilepsy

          -  Schizophrenia

          -  Neuropathic pain and any other pain condition requiring chronic use of pain medication

          -  Known hypersensitivity or allergy (including photoallergy) to NSAID´s including
             ketoprofen and to ingredients of the IMP

          -  Preexisting asthma or bronchospasm after taking aspirin or other NSAIDs

          -  Unable to discontinue analgesic therapy including opioids, NSAID´s, tramadol, muscle
             relaxants, gabapentin, pregabalin, duloxetine, venlafaxine, capsaicine or other drugs
             approved or used for the treatment of pain for the duration of the study
Clinical trial NCT00437112 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: human insulin inhalation powder, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 Diabetes Mellitus

          -  Insulin naive

          -  One or more oral antihyperglycemic medications

          -  HbA1c greater than or equal to 8.0% and less than or equal to 10.5%

          -  Non-smoker

        Exclusion Criteria:

          -  Taking a TZD dose greater than what is indicated

          -  Have not taken insulin within 6 months of entry into study

          -  Have had more than 2 episodes of sever hypoglycemia during the 6 months prior to study
             entry

          -  Have had more than 1 hospitalization or emergency room visit due to poor diabetic
             control during the 6 months prior to study entry

          -  Have had pneumonia in the 3 months prior to study entry

          -  Systemic glucocorticoid therapy

          -  Clinical signs or symptoms of liver disease, acute or chronic hepatitis

          -  History of renal transplantation

          -  Have an active or untreated malignancy

          -  Have a current diagnosis or past history of clinically relevant pulmonary disease

          -  Taking or have taken exenatide during the 6 weeks prior to study entry
Clinical trial NCT00053599 (phase 3, status: completed)
Conditions: alzheimer disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: simvastatin
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        -  Mild to moderate patients with AD who are free of life-threatening disease and who do
             not require lipid-lowering treatment according to current guidelines.

          -  NINCDS/ADRDA criteria for probable AD.

          -  Mini-Mental-State-Exam (MMSE) score between 12 and 26.

          -  Stable medical condition for 3 months prior to the screening visit.

          -  Age greater than or equal to 50 years, and no upper age limit.

          -  Lives in a community dwelling, not in a nursing home.

          -  Stable doses of (non-excluded) medications with central nervous system activity for 4
             weeks prior to the screening visit.

          -  Physical condition acceptable for the study as confirmed by medical history, physical
             exam, neurologic exam and clinical laboratory tests.

          -  Informant/study partner available and willing to accompany participant to all
             scheduled visits and complete informant-based assessments and to supervise
             administration of study medications.

          -  Fluent in English or Spanish.

          -  Modified Hachinski is less than or equal to 4.

        Exclusion criteria:

          -  Coronary heart disease (CHD) including angina, or peripheral vascular disease
             including symptomatic carotid artery disease, or stroke or TIA, as these individuals
             are likely to require treatment with lipid-lowering drugs.

          -  Serious renal disease.

          -  Uncontrolled diabetes.

          -  Triglycerides are greater than 500 mg/dL.

          -  LDL-Cholesterol below 80 mg/dL

          -  Upper limit for the National Cholesterol Education Program (NCEP) guidelines for
             LDL-Cholesterol is 130-190 mg/dL, depending on age and other cardiovascular risk
             factors.

          -  Other indication for the need to treat with lipid-lowering drug.

          -  Active liver disease or persistent elevation in serum transaminase.

          -  Active neoplastic disease (skin tumors other than melanoma are not exclusionary;
             subjects with stable prostate cancer may be included at the discretion of the Project
             Director).

          -  Use of another investigational agent within 2 months of the screening visit.

          -  History of clinically significant stroke.

          -  Current evidence or history in the past 2 years of seizures, head injury with loss of
             consciousness and/or immediate confusion after the injury.

          -  Current DSM-IV criteria based diagnosis for major psychiatric disorder including
             psychosis, major depression, bipolar disorder, alcohol or substance abuse.

          -  Blindness, deafness, language difficulties or any other disability which may prevent
             the subject from participating or cooperating in the protocol.
Clinical trial NCT01103960 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: telmisartan80mg+amlodipine5mg, amlodipine 5mg, telmisartan80mg+amlodipine 5mg
SMILES: CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC
Eligibility criteria:

        Inclusion criteria:

          1. diagnosis of essential hypertension

          2. failure to respond adequately to six weeks treatment with amlodipine 5 mg monotherapy

          3. provision of written informed consent

        Exclusion criteria:

        1. clinical conditions which, in the opinion of the investigator, would not allow safe
        completion of the protocol and safe administration of telmisartan and amlodipine for the
        planned duration of this trial (e.g. populations where labeling of either product
        recommends against its utilization)
Clinical trial NCT00554229 (phase 3, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: zd4054, placebo
SMILES: COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=C1)C1=NN=CO1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Patients who answer TRUE to the following criteria may be eligible to participate in this
        trial.

          1. Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has
             spread to the bone (bone metastases)

          2. Increasing Prostate Specific Antigen (PSA) over a one month period

          3. No pain, or mild pain from prostate cancer

          4. Currently receiving treatment with surgical or medical castration

        Exclusion Criteria:

        Patients who answer TRUE to the following may NOT eligible to participate in this trial.

          1. Currently using opiates based pain killers)

          2. Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone)

          3. Suffering from heart failure or had a myocardial infarction within last 6 months

          4. A history of epilepsy or seizures
Clinical trial NCT00406419 (phase 3, status: terminated)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: methotrexate, ocrelizumab, placebo
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    based on analysis of results and consideration of available treatments, the overall benefit to
    risk profile of ocrelizumab was not favorable in ra.
  
Eligibility criteria:

        Inclusion criteria:

          -  Adult patients, ≥18 years of age

          -  Rheumatoid arthritis for ≥ 3 months

          -  Inadequate clinical response to methotrexate at a dose of 7.5-25mg/week for ≥ 12 weeks

        Exclusion criteria:

          -  Rheumatic autoimmune disease or inflammatory joint disease, other than RA

          -  Prior receipt of any biologic therapy for RA

          -  Concurrent treatment with any DMARD (other than methotrexate)
Clinical trial NCT01194414 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: tocilizumab sc, tocilizumab iv, placebo to tocilizumab sc, placebo to tocilizumab iv, disease-modifying antirheumatic drugs (dmards)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult participants, ≥ 18 years of age

          -  Rheumatoid arthritis of ≥ 6 months duration, according to American College of
             Rheumatology (ACR) criteria

          -  Swollen joint count (SJC) ≥ 4 (66 joint count), tender joint count (TJC) ≥ 4 (68 joint
             count) at screening and baseline

          -  Inadequate response to current DMARD therapy

          -  Permitted DMARDs must be at stable dose for ≥ 8 weeks prior to baseline

          -  Oral corticosteroids (≤ 10 mg/day prednisone or equivalent) and NSAIDs (up to maximum
             recommended dose) must be at stable dose for ≥ 4 weeks prior to baseline

        Exclusion Criteria:

          -  Major surgery (including joint surgery) within 8 weeks prior to screening or planned
             major surgery within 6 months following randomization

          -  Rheumatic autoimmune disease other than RA

          -  Functional class IV (ACR classification)

          -  Diagnosis of juvenile idiopathic arthritis (JIA) or juvenile rheumatoid arthritis
             (JRA) and/or RA before the age of 16

          -  Prior history of or current inflammatory joint disease other than RA

          -  Intra-articular or parenteral corticosteroids within 4 weeks prior to baseline

          -  Previous treatment with tocilizumab

          -  Active current or history of recurrent infection